Search research articles
Contact Us
Filters
Showing results (131-140 of 141) with videos related to
Page
of 15
Sort By:
JTO Clinical and Research Reports
|
September 30, 2021
The Impact of the Availability of Immunotherapy on Patterns of Care in Stage III NSCLC: A Dutch Multicenter Analysis
Merle I Ronden, Idris Bahce, Niels J M Claessens, et al.
Therapeutic Advances in Medical Oncology
|
June 20, 2022
Real-world experience with capmatinib in <i>MET</i> exon 14-mutated non-small cell lung cancer (RECAP): a retrospective analysis from an early access program
Oliver Illini, Hannah Fabikan, Aurélie Swalduz, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 1, 2024
Safety, Efficacy, and Biomarker Analysis of Crizotinib in MET-Mutated Non-Small Cell Lung Cancer-Results from the Drug Rediscovery Protocol
Karlijn Verkerk, Tijmen J W T van der Wel, Laurien J Zeverijn, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 28, 2021
A randomised phase II study of osimertinib and bevacizumab versus osimertinib alone as second-line targeted treatment in advanced NSCLC with confirmed EGFR and acquired T790M mutations: the European Thoracic Oncology Platform (ETOP 10-16) BOOSTER trial
R A Soo, J-Y Han, U Dafni, et al.
Therapeutic Advances in Medical Oncology
|
June 28, 2021
Selpercatinib in RET fusion-positive non-small-cell lung cancer (SIREN): a retrospective analysis of patients treated through an access program
Oliver Illini, Maximilian Johannes Hochmair, Hannah Fabikan, et al.
Frontiers in Oncology
|
March 27, 2023
Therapeutic drug monitoring guided dosing versus standard dosing of alectinib in advanced ALK positive non-small cell lung cancer patients: Study protocol for an international, multicenter phase IV randomized controlled trial (ADAPT ALEC)
Marinda Meertens, M Benthe Muntinghe-Wagenaar, Barend J Sikkema, et al.
Journal for Immunotherapy of Cancer
|
June 22, 2026
Rescue by radiotherapy and anti-CTLA4/PD-1 after failure of anti-PD-1 therapy in patients with metastatic NSCLC: the phase II RECLAIM trial
Ezgi B Ulas, Nora D Purcell, Ilias Houda, et al.
Lung Cancer (Amsterdam, Netherlands)
|
October 21, 2019
ALK immunohistochemistry positive, FISH negative NSCLC is infrequent, but associated with impaired survival following treatment with crizotinib
E Thunnissen, B I Lissenberg-Witte, M M van den Heuvel, et al.
The Oncologist
|
October 28, 2020
Multicenter Comparison of Molecular Tumor Boards in The Netherlands: Definition, Composition, Methods, and Targeted Therapy Recommendations
Bart Koopman, Harry J M Groen, Marjolijn J L Ligtenberg, et al.
Lung Cancer (Amsterdam, Netherlands)
|
October 3, 2025
Determining the optimal approach to identify osimertinib resistance; the first line osimertinib cohort of the OSIRIS study
J W T van der Wel, S M Ernst, M Jebbink, et al.
Page
of 15
Search research articles
Search
Showing results (131-140 of 141) with videos related to
Sort By:
Page
of 15
JTO Clinical and Research Reports
|
September 30, 2021
The Impact of the Availability of Immunotherapy on Patterns of Care in Stage III NSCLC: A Dutch Multicenter Analysis
Merle I Ronden, Idris Bahce, Niels J M Claessens, et al.
Therapeutic Advances in Medical Oncology
|
June 20, 2022
Real-world experience with capmatinib in <i>MET</i> exon 14-mutated non-small cell lung cancer (RECAP): a retrospective analysis from an early access program
Oliver Illini, Hannah Fabikan, Aurélie Swalduz, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 1, 2024
Safety, Efficacy, and Biomarker Analysis of Crizotinib in MET-Mutated Non-Small Cell Lung Cancer-Results from the Drug Rediscovery Protocol
Karlijn Verkerk, Tijmen J W T van der Wel, Laurien J Zeverijn, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 28, 2021
A randomised phase II study of osimertinib and bevacizumab versus osimertinib alone as second-line targeted treatment in advanced NSCLC with confirmed EGFR and acquired T790M mutations: the European Thoracic Oncology Platform (ETOP 10-16) BOOSTER trial
R A Soo, J-Y Han, U Dafni, et al.
Therapeutic Advances in Medical Oncology
|
June 28, 2021
Selpercatinib in RET fusion-positive non-small-cell lung cancer (SIREN): a retrospective analysis of patients treated through an access program
Oliver Illini, Maximilian Johannes Hochmair, Hannah Fabikan, et al.
Frontiers in Oncology
|
March 27, 2023
Therapeutic drug monitoring guided dosing versus standard dosing of alectinib in advanced ALK positive non-small cell lung cancer patients: Study protocol for an international, multicenter phase IV randomized controlled trial (ADAPT ALEC)
Marinda Meertens, M Benthe Muntinghe-Wagenaar, Barend J Sikkema, et al.
Journal for Immunotherapy of Cancer
|
June 22, 2026
Rescue by radiotherapy and anti-CTLA4/PD-1 after failure of anti-PD-1 therapy in patients with metastatic NSCLC: the phase II RECLAIM trial
Ezgi B Ulas, Nora D Purcell, Ilias Houda, et al.
Lung Cancer (Amsterdam, Netherlands)
|
October 21, 2019
ALK immunohistochemistry positive, FISH negative NSCLC is infrequent, but associated with impaired survival following treatment with crizotinib
E Thunnissen, B I Lissenberg-Witte, M M van den Heuvel, et al.
The Oncologist
|
October 28, 2020
Multicenter Comparison of Molecular Tumor Boards in The Netherlands: Definition, Composition, Methods, and Targeted Therapy Recommendations
Bart Koopman, Harry J M Groen, Marjolijn J L Ligtenberg, et al.
Lung Cancer (Amsterdam, Netherlands)
|
October 3, 2025
Determining the optimal approach to identify osimertinib resistance; the first line osimertinib cohort of the OSIRIS study
J W T van der Wel, S M Ernst, M Jebbink, et al.
Page
of 15